Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegcetacoplan in C3 glomerulopathy and IC-MPGN
NCT05067127Phase 3Completed
- Sponsor
- Apellis Pharmaceuticals
- Start
- Nov 2021
- Primary completion
- Jun 2024
- Modality
- PEGylated Peptides
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial in Complement 3 glomerulopathy (C3G) and Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) comparing Pegcetacoplan with Placebo (2 arms). Primary endpoint: Change From Baseline in Log-Transformed Urine Protein-to-Creatinine Ratio at 26 weeks. Started Nov 2021; status: completed.
02
Drugs
pegcetacoplan
03
Conditions
Complement 3 glomerulopathy (C3G)Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Beyond the preview
Go deeper on NCT05067127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05067127.